Views

CrossRef citations to date

Altmetric

Letters to the Editor

Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by streptamer technology

Antje TungerInstitute of Immunology, Medical Faculty, TU Dresden, Dresden, Germany;

Rebekka WehnerInstitute of Immunology, Medical Faculty, TU Dresden, Dresden, Germany; ;National Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany;

Malte von BoninNational Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany; ;Department of Medicine I, University Hospital of Dresden, Dresden, Germany; ;German Cancer Consortium (DKTK), Dresden, Germany; ;German Cancer Research Center (DKFZ), Heidelberg, Germany;

Denise KühnCenter for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;

Falk HeidenreichDepartment of Medicine I, University Hospital of Dresden, Dresden, Germany;

Sarah MatkoInstitute of Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany;

Magdalena NauerthInstitute for Medical Microbiology, Immunology and Hygiene, TU Munich, Munich, Germany;

Elke Rücker-BraunDepartment of Medicine I, University Hospital of Dresden, Dresden, Germany;

Sevina DietzCenter for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;

Cornelia S. LinkDepartment of Medicine I, University Hospital of Dresden, Dresden, Germany; ;Center for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;

Anne EugsterCenter for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;

Marcus OdendahlInstitute of Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany;

Dirk H. BuschInstitute for Medical Microbiology, Immunology and Hygiene, TU Munich, Munich, Germany;

Torsten TonnGerman Cancer Consortium (DKTK), Dresden, Germany; ;German Cancer Research Center (DKFZ), Heidelberg, Germany; ;Center for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany; ;Institute of Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany;

Ezio BonifacioCenter for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;

Lothar GermerothJuno Therapeutics GmbH, Göttingen, Germany;

Johannes ScheteligDepartment of Medicine I, University Hospital of Dresden, Dresden, Germany;

Michael P. BachmannNational Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany; ;German Cancer Consortium (DKTK), Dresden, Germany; ;German Cancer Research Center (DKFZ), Heidelberg, Germany; ;Center for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany; ;Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz Center Dresden-Rossendorf, Dresden, Germany

Martin BornhäuserNational Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany; ;Department of Medicine I, University Hospital of Dresden, Dresden, Germany; ;German Cancer Consortium (DKTK), Dresden, Germany; ;German Cancer Research Center (DKFZ), Heidelberg, Germany; ;Center for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;

Marc SchmitzInstitute of Immunology, Medical Faculty, TU Dresden, Dresden, Germany; ;National Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany; ;German Cancer Consortium (DKTK), Dresden, Germany; ;German Cancer Research Center (DKFZ), Heidelberg, Germany; ;Center for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany; Correspondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Acknowledgements

This work was supported by grants from the Bundesministerium für Bildung und Forschung (BMBF) to M.O., J.S., T.T., M.B., and M.S., the Bayerische Forschungsstiftung (ForbiMed) to M.N. and D.H.B. and the Graduiertenakademie TU Dresden to A.T.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http://dx.doi.org/10.1080/10428194.2016.1233538.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by streptamer technology

Information for

Open access

Opportunities

Help and information

Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by streptamer technology

Acknowledgements

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature